• Abbott plans to separate its Nutrition business into an independent, publicly traded company by the end of 2027.
• The new company will have approximately $8.5 billion in annual sales, with brands including Similac, Ensure and PediaSure.
• The remaining business will have approximately $42 billion in sales, focused on medical devices, diagnostics and established medicines.
• Shareholders will receive shares in the new company, with combined dividends expected to equal the existing dividend at separation.
• Daniel Salvadori, executive vice president and group president of Established Pharmaceuticals and Nutritional Products, will lead the new company.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbott Laboratories published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610210725PR_NEWS_USPR_____CG77278) on October 21, 2026, and is solely responsible for the information contained therein.